SusanM.O'BrienMD

PubMed

• Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
  Susan O'Brien> ;Clinical Advances in Hematology & Oncology. 2021 Oct 1
• 9 citations
  Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propen...
  Koji Sasaki, Hagop M. Kantarjian, Kiyomi Morita, Nicholas J. Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Sa Wang, Joseph D. Khoury, J...> ;Cancer. 2021 Sep 15
• 16 citations
  Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
  Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta, Susan O'Brien, Jacqueline C. Barrientos, Jose F. Leis, Cong Ch...> ;Blood. 2021 Aug 18
• 4 citations
  Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
  Jennifer A. Woyach, Alessandra Tedeschi, Talha Munir, Tanya Siddiqi, Peter Hillmen, John C. Byrd, Paolo Ghia, Stephen P. Mulligan, Sandra Dai, Carlos I. Amaya-Chanaga,...> ;Leukemia & Lymphoma. 2021 Aug 13
• 18 citations
  Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
  Amit Bar-Or, Susan O'Brien, Michael Sweeney, Edward Fox, Jeffrey A. Cohen> ;CNS Drugs. 2021 Aug 9
• 181 citations
  Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
  John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E. Kay, José A. G...> ;Journal of Clinical Oncology. 2021 Jul 26
• 5 citations
  Frontline Management of CLL in 2021
  Elizabeth Brem, Susan O'Brien> ;JCO Oncology Practice. 2021 Jul 21
• 3 citations
  An update on acalabrutinib to treat chronic lymphocytic leukemia.
  Amanda L. Blackmon, Susan O'Brien> ;Drugs of Today. 2021 Jul 1
• 39 citations
  Acalabrutinib in treatment-naive chronic lymphocytic leukemia
  John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, P...> ;Blood. 2021 Jun 17
• 22 citations
  Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia...
  Elias Jabbour, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Rashmi Kanagal-Shamanna, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Ke...> ;Cancer. 2021 Jun 15
• 19 citations
  Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
  Nitin Jain, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju...> ;Leukemia. 2021 May 18
• 2 citations
  Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
  Hua Jay J. Cherng, Nadya Jammal, Shilpa Paul, Xuemei Wang, Koji Sasaki, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Zeev Estrov, Susan O'Brien, Michael J....> ;British Journal of Haematology. 2021 May 10
• 9 citations
  Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant
  Bachar Samra, Hagop M. Kantarjian, Koji Sasaki, Ahmad S. Alotaibi, Marina Konopleva, Susan O'Brien, Alessandra Ferrajoli, Rebecca Garris, Cesar Nunez, Tapan M. Kadia, ...> ;Acta Haematologica. 2021 May 1
• 18 citations
  Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
  Richard R. Furman, John C. Byrd, Roger G. Owen, Susan O'Brien, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Nataliya Chernyukhin, Tamara Lezhava, Ahmed Hamdy...> ;Leukemia. 2021 Apr 27
• 24 citations
  Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
  Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Gökbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil Merchant, Ryan D. Cas...> ;Cancer. 2021 Mar 15
• 13 citations
  Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
  Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, ...> ;Clinical Cancer Research. 2021 Feb 18
• 6 citations
  Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
  Musa Yilmaz, Hagop M. Kantarjian, Gokce Altay Toruner, C. Cameron Yin, Rashmi Kanagal-Shamanna, Jorge E. Cortes, Ghayyas Issa, Nicholas J. Short, Joseph D. Khoury, Gui...> ;Leukemia & Lymphoma. 2021 Jan 2
• 10 citations
  Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare).
  Anthony R. Mato, Matthew S. Davids, Jeff P. Sharman, Lindsey E. Roeker, Neil E. Kay, Arnon P. Kater, Kerry A. Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Ala...> ;Clinical Cancer Research. 2021 Jan 1
• 6 citations
  Minimal Residual Disease in Acute Myeloid Leukemia.
  Deepa Jeyakumar, Susan O'Brien> ;JAMA Oncology. 2020 Dec 1
• Highlights in chronic lymphocytic leukemia from the 2020 American Society of Clinical Oncology Annual Meeting: commentary.
  Susan O'Brien> ;Clinical Advances in Hematology & Oncology. 2020 Sep 1
• 5 citations
  Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin
  Ryan D. Cassaday, David I. Marks, Daniel J. DeAngelo, Elias Jabbour, Anjali S. Advani, Susan O'Brien, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop M. Kantarjian...> ;British Journal of Haematology. 2020 Aug 17
• 7 citations
  Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies
  Tsering Gyalpo Lama, Daniel Kyung, Susan O'Brien> ;Expert Review of Hematology. 2020 Aug 12
• 38 citations
  Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
  Isabelle G. Solman, Lisa K. Blum, Hana Y. Hoh, Thomas J. Kipps, Jan A. Burger, Jacqueline C. Barrientos, Susan O'Brien, Stephen P. Mulligan, Neil E. Kay, Peter Hillmen...> ;Leukemia Research. 2020 Aug 11
• 29 citations
  Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
  Daniel J. DeAngelo, Anjali S. Advani, David I. Marks, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Elias Jabbour, Akil Merchant, Tao Wang, Erik V...> ;Blood Cancer Journal. 2020 Aug 7
• 6 citations
  Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib
  Jennifer R. Brown, Andrew D. Zelenetz, Richard R. Furman, Nicole Lamanna, Anthony R. Mato, Marco Montillo, Susan O'Brien, Ronald L. Dubowy, Lin Gu, Veerendra Munugalav...> ;Leukemia. 2020 Jul 12
• Join now to see all

Abstracts/Posters

• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
  Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Susan M. o'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
  Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia 
  60th American Society of Hematology Annual Meeting - 11/30/2018